Akums Drugs and Pharmaceuticals Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Akums Drugs and Pharmaceuticals Ltd filed with BSE on 13 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Akums Drugs & Pharmaceuticals reported Q1 FY27 revenue of Rs 1,167 crores, up 13.9% year-on-year, with EBITDA of Rs 175 crores, up 35.4% year-on-year, driven primarily by the CDMO segment. Management said domestic and international branded formulation segments saw muted quarterly performances while API and trade generics segments performed in line with prior guidance. The company also announced the acquisition of Oriflame India's manufacturing business, covering facilities in Roorkee and Noida, to expand into skin care cosmetics and wellness products.
Numbers mentioned
Revenue: INR1,167 crores (Q1 FY27)
p. 4
“Our operating revenue stood at INR1,167 crores, an increase of 13.9% year-on-year.”
Sumeet Sood, page 4 of the filed PDF · View the filing
EBITDA: INR175 crores (Q1 FY27)
p. 4
“The operating EBITDA for the quarter was INR175 crores, an increase of 35.4% year-on-year.”
Sumeet Sood, page 4 of the filed PDF · View the filing
EBITDA margin: 15% (Q1 FY27)
p. 4
“Margins were robust at 15%, improving 238 basis points year-on-year.”
Sumeet Sood, page 4 of the filed PDF · View the filing
PAT: INR101 crores (Q1 FY27)
p. 4
“The PAT of the company stood at INR101 crores, an increase of 56.1% year-on-year.”
Sumeet Sood, page 4 of the filed PDF · View the filing
CDMO revenue: INR964 crores (Q1 FY27)
p. 4
“if we start with the CDMO, the revenue stood at INR964 crores, increase of 18.6% year-on-year”
Sumeet Sood, page 4 of the filed PDF · View the filing
Domestic branded formulation revenue: INR115 crores (Q1 FY27)
p. 5
“Domestic branded formulation stood at INR115 crores, an increase of 7.3% year-on-year and an increase of 12.9% quarter-on-quarter.”
Sumeet Sood, page 5 of the filed PDF · View the filing
International branded formulation revenue: INR35 crores (Q1 FY27)
p. 5
“For the international branded formulation business, the revenue stood at INR35 crores, a decline of 1.5%”
Sumeet Sood, page 5 of the filed PDF · View the filing
API revenue: INR32 crores (Q1 FY27)
p. 5
“API revenue stood at INR32 crores, a decline of 29.7% year-on-year”
Sumeet Sood, page 5 of the filed PDF · View the filing
Trade generic revenue: INR21 crores (Q1 FY27)
p. 5
“Trade generic business stood at INR21 crores, a decrease of 9.5% year-on-year and a decrease of 23.4% quarter-on-quarter.”
Sumeet Sood, page 5 of the filed PDF · View the filing
Cash surplus: INR1,616 crores (Q1 FY27)
p. 5
“Our balance sheet continues to remain very healthy with a cash surplus of INR1,616 crores.”
Sumeet Sood, page 5 of the filed PDF · View the filing
Operating cash flow: INR65 crores (Q1 FY27)
p. 5
“The operating cash flow for the company for the quarter 1 stood at INR65 crores.”
Sumeet Sood, page 5 of the filed PDF · View the filing
Net worth: more than INR3,400 crores
p. 12
“our net worth sits at more than INR3,400 crores and there is no debt on the company.”
Sumeet Sood, page 12 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
CDMO EBITDA margin — 14% to 15% · FY27
stated firmly by Sahil Maheshwari
p. 6
“we have always guided for a 14% to 15% margin”
Sahil Maheshwari, page 6 of the filed PDF · View the filing
Zambia revenue — $25 million, roughly INR240-odd crores · H2 FY27
stated conditionally by Sahil Maheshwari
p. 8
“Zambia is something we expect in the H2 that we deliver for this fiscal, the $25 million, which will roughly translate to almost INR240-odd crores in our revenue.”
Sahil Maheshwari, page 8 of the filed PDF · View the filing
Zambia revenue recognition — Q3 and Q4 FY27
stated firmly by Sahil Maheshwari
p. 9
“So it will likely be in Q3 and maybe some parts in Q4.”
Sahil Maheshwari, page 9 of the filed PDF · View the filing
Volume growth — double digits · coming quarters
stated firmly by Sahil Maheshwari
p. 7
“we remain confident that our volume growth will at least be double digits in the coming quarters.”
Sahil Maheshwari, page 7 of the filed PDF · View the filing
API segment EBITDA breakeven — monthly EBITDA positive · by end of February, March
stated firmly by Sahil Maheshwari
p. 12
“the whole target is on a monthly level, at least by the end of February, March, we should be monthly EBITDA positive in this business.”
Sahil Maheshwari, page 12 of the filed PDF · View the filing
API segment profitability contribution — positively contributing to profit · next year
stated conditionally by Sahil Maheshwari
p. 12
“And then next year, we should start positively contributing to the profit from this segment.”
Sahil Maheshwari, page 12 of the filed PDF · View the filing
Peak capacity utilization — 55%, 58%, 60-odd percent
stated as an aspiration by Sahil Maheshwari
p. 8
“we could move up to 55%, 58%, 60-odd percent as our total peak utilization.”
Sahil Maheshwari, page 8 of the filed PDF · View the filing
Baddi facility commissioning — end of this financial year
stated firmly by Sahil Maheshwari
p. 10
“we are in the process of setting up one more facility in Baddi, which will go live in the -- almost at the end of this financial year itself, which will significantly boost our oral manufacturing capabilities, right?”
Sahil Maheshwari, page 10 of the filed PDF · View the filing
Domestic MR productivity — industry averages and hopefully surpass them
stated as an aspiration by Sahil Maheshwari
p. 13
“gradually, as the business will scale up, we'll certainly inch up to the industry averages and hopefully surpass them.”
Sahil Maheshwari, page 13 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said Q2 volumes look healthy in high teens and expects margins to remain in the 14-15% range, possibly toward the upper end.
Answered by Sahil Maheshwari
Asked by Vivek Agarwal: What is the outlook for CDMO volume and value growth, and margin trajectory?
p. 6
“Margins are expected to remain at similar levels, right? So we have always guided for a 14% to 15% margin.”
Sahil Maheshwari, page 6 of the filed PDF · View the filing
Management said volume growth has been in high teens and expects at least double-digit volume growth in coming quarters.
Answered by Sahil Maheshwari
Asked by Pooja: What is the outlook on volume growth for FY27 given IPM growth acceleration?
p. 7
“we remain confident that our volume growth will at least be double digits in the coming quarters.”
Sahil Maheshwari, page 7 of the filed PDF · View the filing
Management said it remains committed to the API business and expects Zambia and European margins to be in higher teens compared to current CDMO margins.
Answered by Sahil Maheshwari
Asked by Andrey: Is there a timeframe for evaluating whether to continue the API business, and what are updated margin guidances for Zambia and Europe?
p. 7
“So the management is fully confident, right? So this is a business we have been investing for over 3, 4 years now.”
Sahil Maheshwari, page 7 of the filed PDF · View the filing
Management confirmed Zambia supply is on track for Q3/Q4 recognition and confirmed the cash figure is net of debt.
Answered by Sahil Maheshwari
Asked by Bhavin Chheda: Has the Zambia business started, and is the INR1,600 crores figure net of debt?
p. 9
“So I think we always maintained, which is there, right? So it will likely be in Q3 and maybe some parts in Q4.”
Sahil Maheshwari, page 9 of the filed PDF · View the filing
Management described it as expanding manufacturing footprint into skin care cosmetics and enabling entry into color cosmetics.
Answered by Sahil Maheshwari
Asked by Praveen Jayaraman: Is the Oriflame acquisition a capability or capacity acquisition, and how will it add value?
p. 10
“the acquisition rationale behind this is to expand our capacities into the skin care cosmetics as well as this will enable us to venture out into the color cosmetics as well, which is a fast-growing space.”
Sahil Maheshwari, page 10 of the filed PDF · View the filing
Management said most improvement came from high-value products, with limited inventory gains, and noted API cogs improved.
Answered by Sahil Maheshwari
Asked by Akshay Shah: How much of the gross margin improvement is due to value addition versus inventory gains?
p. 11
“So very limited would be of inventory gains per se. Most of it is largely through high-value products being getting added.”
Sahil Maheshwari, page 11 of the filed PDF · View the filing
Management confirmed the target of monthly EBITDA positive by February/March and positive profit contribution the following year.
Answered by Sahil Maheshwari
Asked by Abdulkader Puranwala: Is the company still holding to its guidance of API segment turning profitable by end of FY27, and growth by FY28?
p. 12
“Absolutely right, Abdul. So the whole target is on a monthly level, at least by the end of February, March, we should be monthly EBITDA positive in this business.”
Sahil Maheshwari, page 12 of the filed PDF · View the filing
Management said most of the cash is in fixed deposits with nationalized banks and will be used for value-accretive acquisitions.
Answered by Sumeet Sood
Asked by Abdulkader Puranwala: Where is the INR1,600 crores cash parked and how will it be used?
p. 12
“Most of the money, in fact, 98% of the money is parked in fixed deposits with nationalized banks, right?”
Sumeet Sood, page 12 of the filed PDF · View the filing
Management said the expansion aims to build clinical presence and tap new geographies, and productivity should improve as the business matures.
Answered by Sahil Maheshwari
Asked by Akshay Shah: Why is the company increasing MR headcount despite lower sales force productivity than industry?
p. 13
“So as you rightly said, we are lower than the industry average benchmarks, right? So the strategy has always been to have a strong clinical presence across our focused power products, right?”
Sahil Maheshwari, page 13 of the filed PDF · View the filing
Risks flagged
API prices are volatile
p. 5
“API prices, they are volatile, right?”
Sahil Maheshwari, page 5 of the filed PDF · View the filing
Domestic branded formulation margins impacted by increased employee strength
p. 4
“Margins were impacted due to an increase in employee strength.”
Sandeep Jain, page 4 of the filed PDF · View the filing
International branded formulation business had a muted quarter
p. 4
“Our international branded formulation business had a muted quarter, but is expected to return to growth as we remain confident in the structural attractiveness of our chosen geographies.”
Sandeep Jain, page 4 of the filed PDF · View the filing
Marketing segments saw muted quarterly performances
p. 3
“Marketing segments, domestic as well as exports saw muted quarterly performances with multiple initiatives underway.”
Sandeep Jain, page 3 of the filed PDF · View the filing
API segment continues to report EBITDA losses
p. 5
“EBITDA for the quarter was at minus INR4 crores.”
Sumeet Sood, page 5 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.